Mouse models of liver cancer

Methods in Molecular Biology

Volumn 1267, Issue , 2015, Pages 165-183

  Caviglia, Jorge Matias ^a   Schwabe, Robert F ^a  

^a NONE

Author keywords

Carcinogenesis; Cholangiocarcinoma; Hepatocellular adenoma; Hepatocellular carcinoma; Liver

Indexed keywords

ARTICLE; CANCER GROWTH; GENETIC MANIPULATION; GENETIC VARIABILITY; HUMAN; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER DEVELOPMENT; LIVER FIBROSIS; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; SEX DIFFERENCE; TUMOR MICROENVIRONMENT; ANIMAL; ANTIBODY SPECIFICITY; CELL TRANSFORMATION; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENE INACTIVATION; GENETICS; LIVER; LIVER TUMOR; MALE; METABOLISM; MOUSE; PATHOLOGY; TUMOR CELL LINE;

CARBON TETRACHLORIDE; DIETHYLNITROSAMINE; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MULTIDRUG RESISTANCE PROTEIN; P-GLYCOPROTEIN 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANIMALS; CARBON TETRACHLORIDE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DIETHYLNITROSAMINE; DISEASE MODELS, ANIMAL; FEMALE; GENE KNOCKOUT TECHNIQUES; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MAP KINASE KINASE KINASES; MICE; ORGAN SPECIFICITY; P-GLYCOPROTEINS; PTEN PHOSPHOHYDROLASE;

EID: 84954602996     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-2297-0_8     Document Type: Article

References (86)

1. Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379(9822): 1245-1255. doi: 10.1016/s0140-6736(11) 61347-0
2. El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365(12):1118-1127. doi: 10.1056/NEJMra1001683
3. Fausto N, Campbell JS (2010) Mouse models of hepatocellular carcinoma. Semin Liver Dis 30(1):87-98. doi: 10.1055/s-0030-1247135
4. Heindryckx F, Colle I, Van Vlierberghe H (2009) Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol 90(4):367-386. doi: 10.1111/j.1365-2613. 2009.00656.x
5. Leenders MW, Nijkamp MW, Borel Rinkes IH (2008) Mouse models in liver cancer research: a review of current literature. World J Gastroenterol 14(45):6915-6923
6. Newell P, Villanueva A, Friedman SL, Koike K, Llovet JM (2008) Experimental models of hepatocellular carcinoma. J Hepatol 48(5): 858-879. doi: 10.1016/j.jhep.2008.01.008
7. Dragani TA, Manenti G, Gariboldi M, De Gregorio L, Pierotti MA (1995) Genetics of liver tumor susceptibility in mice. Toxicol Lett 82-83:613-619
8. Feo F, De Miglio MR, Simile MM, Muroni MR, Calvisi DF, Frau M, Pascale RM (2006) Hepatocellular carcinoma as a complex polygenic disease. Interpretive analysis of recent developments on genetic predisposition. Biochim Biophys Acta 1765(2):126-147. doi: 10.1016/j.bbcan.2005.08.007
9. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clement B, Balabaud C, Chevet E, Laurent A, Couchy G, Letouze E, Calvo F, Zucman-Rossi J (2012) Integrated analysis of somatic mutations and focal copy-number changes identifi es key genes and pathways in hepatocellular carcinoma. Nat Genet 44(6):694-698. doi: 10.1038/ng.2256
10. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, Arai Y, Takahashi H, Shirakihara T, Nagasaki M, Shibuya T, Nakano K, Watanabe-Makino K, Tanaka H, Nakamura H, Kusuda J, Ojima H, Shimada K, Okusaka T, Ueno M, Shigekawa Y, Kawakami Y, Arihiro K, Ohdan H, Gotoh K, Ishikawa O, Ariizumi S, Yamamoto M, Yamada T, Chayama K, Kosuge T, Yamaue H, Kamatani N, Miyano S, Nakagama H, Nakamura Y, Tsunoda T, Shibata T, Nakagawa H (2012) Whole-genome sequencing of liver cancers identifi es etiological infl uences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 44(7):760-764. doi: 10.1038/ng.2291
11. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM (2007) Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27(1):55-76. doi: 10.1055/ s-2006-960171
12. Ozturk M (1991) p53 mutation in hepatocellular carcinoma after afl atoxin exposure. Lancet 338(8779):1356-1359
13. Simonetti RG, Camma C, Fiorello F, Politi F, D’Amico G, Pagliaro L (1991) Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 36(7):962-972
14. Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127(5 Suppl 1):S35-S50
15. Luedde T, Schwabe RF (2011) NF-kappaB in the liver-linking injury, fi brosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 8(2):108-118. doi: 10.1038/nrgastro. 2010.213
16. Robinson WS (1994) Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma. Annu Rev Med 45:297-323. doi: 10.1146/annurev.med.45.1.297
17. Malato Y, Naqvi S, Schurmann N, Ng R, Wang B, Zape J, Kay MA, Grimm D, Willenbring H (2011) Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J Clin Invest 121(12):4850-4860. doi: 10.1172/ JCI59261, 59261 [pii]
18. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK, Thorgeirsson SS (2004) Application of comparative functional genomics to identify best-fi t mouse models to study human cancer. Nat Genet 36(12):1306-1311. doi: 10.1038/ng1481
19. Hill-Baskin AE, Markiewski MM, Buchner DA, Shao H, DeSantis D, Hsiao G, Subramaniam S, Berger NA, Croniger C, Lambris JD, Nadeau JH (2009) Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum Mol Genet 18(16):2975-2988. doi: 10.1093/hmg/ddp236
20. Bettermann K, Vucur M, Haybaeck J, Koppe C, Janssen J, Heymann F, Weber A, Weiskirchen R, Liedtke C, Gassler N, Muller M, de Vos R, Wolf MJ, Boege Y, Seleznik GM, Zeller N, Erny D, Fuchs T, Zoller S, Cairo S, Buendia MA, Prinz M, Akira S, Tacke F, Heikenwalder M, Trautwein C, Luedde T (2010) TAK1 suppresses a NEMO-dependent but NFkappaB-independent pathway to liver cancer. Cancer Cell 17(5):481-496. doi: 10.1016/ j.ccr.2010.03.021
21. Inokuchi S, Aoyama T, Miura K, Osterreicher CH, Kodama Y, Miyai K, Akira S, Brenner DA, Seki E (2010) Disruption of TAK1 in hepatocytes causes hepatic injury, infl ammation, fi brosis, and carcinogenesis. Proc Natl Acad Sci U S A 107(2):844-849. doi: 10.1073/ pnas.0909781107
22. Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, van Roon MA et al (1993) Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75(3):451-462
23. Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, Pasparakis M (2007) Deletion of NEMO/ IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11(2):119-132. doi: 10.1016/j. ccr.2006.12.016
24. Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, Caviglia JM, Khiabanian H, Adeyemi A, Bataller R, Lefkowitch JH, Bower M, Friedman R, Sartor RB, Rabadan R, Schwabe RF (2012) Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21(4):504-516. doi: 10.1016/j.ccr.2012.02.007
25. Matsuda M, Nakamoto Y, Suzuki S, Kurata T, Kaneko S (2005) Interferon-gamma-mediated hepatocarcinogenesis in mice treated with diethylnitrosamine. Lab Invest 85(5):655-663. doi: 10.1038/labinvest.3700257, 3700257 [pii]
26. Campbell JS, Hughes SD, Gilbertson DG, Palmer TE, Holdren MS, Haran AC, Odell MM, Bauer RL, Ren HP, Haugen HS, Yeh MM, Fausto N (2005) Platelet-derived growth factor C induces liver fi brosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci U S A 102(9):3389-3394. doi: 10.1073/pnas. 0409722102
27. Schnur J, Nagy P, Sebestyen A, Schaff Z, Thorgeirsson SS (1999) Chemical hepatocarcinogenesis in transgenic mice overexpressing mature TGF beta-1 in liver. Eur J Cancer 35(13):1842-1845
28. Li Y, Tang Z-Y, Hou J-X (2012) Hepatocellular carcinoma: insight from animal models. Nat Rev Gastroenterol Hepatol 9(1):32-43
29. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M (2010) Dietary and genetic obesity promote liver infl ammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140(2): 197-208. doi: 10.1016/j.cell.2009.12.052
30. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, Iwakura Y, Oshima K, Morita H, Hattori M, Honda K, Ishikawa Y, Hara E, Ohtani N (2013) Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499: 97-101. doi: 10.1038/nature12347
31. Charlton M, Krishnan A, Viker K, Sanderson S, Cazanave S, McConico A, Masuoko H, Gores G (2011) Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fi brosis, and high physiological fi delity to the human condition. Am J Physiol Gastrointest Liver Physiol 301(5):G825-G834. doi: 10.1152/ajpgi.00145.2011
32. Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, Saxena V, Tang PH, Miles L, Miles MV, Balistreri WF, Woods SC, Seeley RJ (2010) High-fructose, medium chain trans fat diet induces liver fi brosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 52(3): 934-944. doi: 10.1002/hep.23797
33. Bagi CM, Andresen CJ (2010) Models of hepatocellular carcinoma and biomarker strategy. Cancers 2(3):1441-1452. doi: 10.3390/ cancers2031441
34. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, Lopez CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, Calvano SE, Mason PH, Cobb JP, Rahme LG, Lowry SF, Maier RV, Moldawer LL, Herndon DN, Davis RW, Xiao W, Tompkins RG, Infl ammation, Host Response to Injury LSCRP (2013) Genomic responses in mouse models poorly mimic human infl ammatory diseases. Proc Natl Acad Sci U S A 110(9):3507-3512. doi: 10.1073/pnas.1222878110
35. Grompe M, Strom S (2013) Mice with human livers. Gastroenterology 145(6):1209-1214. d o i: 10.1053/j.gastro.2013.09.009, S0016-5085(13)01308-5 [pii]
36. Vesselinovitch SD, Mihailovich N (1983) Kinetics of diethylnitrosamine hepatocarcinogenesis in the infant mouse. Cancer Res 43(9):4253-4259
37. Vesselinovitch SD, Koka M, Mihailovich N, Rao KV (1984) Carcinogenicity of diethylnitrosamine in newborn, infant, and adult mice. J Cancer Res Clin Oncol 108(1):60-65
38. Verna L, Whysner J, Williams GM (1996) N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol Ther 71(1-2):57-81
39. Diwan BA, Rice JM, Ward JM (1990) Straindependent effects of phenobarbital on liver tumor promotion in inbred mice. Prog Clin Biol Res 331:69-83
40. Tokumo K, Iatropoulos MJ, Williams GM (1991) Butylated hydroxytoluene lacks the activity of phenobarbital in enhancing diethylnitrosamine-induced mouse liver carcinogenesis. Cancer Lett 59(3):193-199
41. Uehara T, Ainslie GR, Kutanzi K, Pogribny IP, Muskhelishvili L, Izawa T, Yamate J, Kosyk O, Shymonyak S, Bradford BU, Boorman GA, Bataller R, Rusyn I (2013) Molecular mechanisms of fi brosis-associated promotion of liver carcinogenesis. Toxicol Sci 132(1):53-63. doi: 10.1093/toxsci/kfs342, kfs342 [pii]
42. Ruetz S, Gros P (1994) Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 77(7):1071-1081
43. Mauad TH, van Nieuwkerk CM, Dingemans KP, Smit JJ, Schinkel AH, Notenboom RG, van.den.Bergh.Weerman MA, Verkruisen RP, Groen AK, Oude Elferink RP et al (1994) Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative infl ammatory cholangitis and hepatocarcinogenesis. Am J Pathol 145(5):1237-1245
44. Katzenellenbogen M, Mizrahi L, Pappo O, Klopstock N, Olam D, Jacob-Hirsch J, Amariglio N, Rechavi G, Domany E, Galun E, Goldenberg D (2007) Molecular mechanisms of liver carcinogenesis in the mdr2-knockout mice. Mol Cancer Res 5(11):1159-1170. doi: 10.1158/1541-7786.mcr-07-0172
45. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y (2004) NF-kappaB functions as a tumour promoter in infl ammation-associated cancer. Nature 431(7007):461-466. doi: 10.1038/ nature02924
46. Vucur M, Reisinger F, Gautheron J, Janssen J, Roderburg C, Cardenas DV, Kreggenwinkel K, Koppe C, Hammerich L, Hakem R, Unger K, Weber A, Gassler N, Luedde M, Frey N, Neumann UP, Tacke F, Trautwein C, Heikenwalder M, Luedde T (2013) RIP3 inhibits infl ammatory hepatocarcinogenesis but promotes cholestasis by controlling caspase-8-and JNK-dependent compensatory cell proliferation. Cell Rep 4(4):776-790. d o i: 10.1016/j.celr ep.2013.07.035, S2211-1247(13)00397-5 [pii]
47. Song MS, Salmena L, Pandolfi PP (2012) The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 13(5):283-296. doi: 10.1038/nrm3330
48. Hollander MC, Blumenthal GM, Dennis PA (2011) PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 11(4):289-301. doi: 10.1038/nrc3037
49. Dong-Dong L, Xi-Ran Z, Xiang-Rong C (2003) Expression and signifi cance of new tumor suppressor gene PTEN in primary liver cancer. J Cell Mol Med 7(1):67-71
50. Hu TH, Huang CC, Lin PR, Chang HW, Ger LP, Lin YW, Changchien CS, Lee CM, Tai MH (2003) Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/ TEP1 in hepatocellular carcinoma. Cancer 97(8):1929-1940. doi: 10.1002/cncr.11266
51. Yao YJ, Ping XL, Zhang H, Chen FF, Lee PK, Ahsan H, Chen CJ, Lee PH, Peacocke M, Santella RM, Tsou HC (1999) PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene 18(20):3181-3185. doi: 10.1038/ sj.onc.1202659
52. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP (1998) Pten is essential for embryonic development and tumour suppression. Nat Genet 19(4):348-355. doi: 10.1038/1235
53. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R (1999) Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A 96(4):1563-1568
54. Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, Mizuno K, Hasegawa G, Kishimoto H, Iizuka M, Naito M, Enomoto K, Watanabe S, Mak TW, Nakano T (2004) Hepatocyte-specifi c Pten defi ciency results insteatohepatitis and hepatocellular carcinomas. J Clin Invest 113(12):1774-1783. doi: 10.1172/ jci20513
55. Watanabe S, Horie Y, Kataoka E, Sato W, Dohmen T, Ohshima S, Goto T, Suzuki A (2007) Non-alcoholic steatohepatitis and hepatocellular carcinoma: lessons from hepatocyte-specifi c phosphatase and tensin homolog (PTEN)-defi cient mice. J Gastroenterol Hepatol 22(Suppl 1):S96-S100. doi: 10.1111/j.1440-1746.2006.04665.x
56. He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, Jiang Y, Shalapour S, Seki E, Yost SE, Jepsen K, Frazer KA, Harismendy O, Hatziapostolou M, Iliopoulos D, Suetsugu A, Hoffman RM, Tateishi R, Koike K, Karin M (2013) Identifi cation of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 155(2):384-396. doi: 10.1016/j.cell.2013.09.031
57. Schmitz V, Tirado-Ledo L, Tiemann K, Raskopf E, Heinicke T, Ziske C, Gonzalez-Carmona MA, Rabe C, Wernert N, Prieto J, Qian C, Sauerbruch T, Caselmann WH (2004) Establishment of an orthotopic tumour model for hepatocellular carcinoma and non-invasive in vivo tumour imaging by high resolution ultrasound in mice. J Hepatol 40(5):787-791. doi: 10.1016/j.jhep.2004.01.010
58. Abushahba W, Balan M, Castaneda I, Yuan Y, Reuhl K, Raveche E, de la Torre A, Lasfar A, Kotenko SV (2010) Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother 59(7): 1059-1071. doi: 10.1007/s00262-010-0831-3
59. Kornek M, Raskopf E, Tolba R, Becker U, Klockner M, Sauerbruch T, Schmitz V (2008) Accelerated orthotopic hepatocellular carcinomas growth is linked to increased expression of pro-angiogenic and prometastatic factors in murine liver fi brosis. Liver Int 28(4):509-518. doi: 10.1111/j.1478-3231.2008.01670.x
60. Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, Kawai T, Matsumoto K, Takeuchi O, Akira S (2005) Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 6(11):1087-1095. doi: 10.1038/ni1255
61. Xie M, Zhang D, Dyck JR, Li Y, Zhang H, Morishima M, Mann DL, Taffet GE, Baldini A, Khoury DS, Schneider MD (2006) A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci U S A 103(46):17378-17383. doi: 10.1073/ pnas.0604708103
62. Machida K, Chen CL, Liu JC, Kashiwabara C, Feldman D, French SW, Sher L, Hyeongnam JJ, Tsukamoto H (2012) Cancer stem cells generated by alcohol, diabetes, and hepatitis C virus. J Gastroenterol Hepatol 27(Suppl 2):19-22. doi: 10.1111/j.1440-1746.2011.07010.x
63. Thorgeirsson SS, Santoni-Rugiu E (1996) Transgenic mouse models in carcinogenesis: interaction of c-myc with transforming growth factor alpha and hepatocyte growth factor in hepatocarcinogenesis. Br J Clin Pharmacol 42(1):43-52
64. Colnot S, Decaens T, Niwa-Kawakita M, Godard C, Hamard G, Kahn A, Giovannini M, Perret C (2004) Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci U S A 101(49):17216-17221. doi: 10.1073/pnas.0404761101
65. Harada N, Oshima H, Katoh M, Tamai Y, Oshima M, Taketo MM (2004) Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Res 64(1): 48-54
66. Nejak-Bowen KN, Monga SP (2011) Betacatenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol 21(1):44-58. doi: 10.1016/ j.semcancer.2010.12.010
67. Katz SF, Lechel A, Obenauf AC, Begus-Nahrmann Y, Kraus JM, Hoffmann EM, Duda J, Eshraghi P, Hartmann D, Liss B, Schirmacher P, Kestler HA, Speicher MR, Rudolph KL (2012) Disruption of Trp53 in livers of mice induces formation of carcinomas with bilineal differentiation. Gastroenterology 142(5):1229-1239. e1223. doi: 10.1053/j.gastro.2012.02.009
68. Jhappan C, Stahle C, Harkins RN, Fausto N, Smith GH, Merlino GT (1990) TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 61(6): 1137-1146
69. Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM (2001) Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 153(5):1023-1034
70. Vesselinovitch SD, Mihailovich N, Wogan GN, Lombard LS, Rao KV (1972) Afl atoxin B 1, a hepatocarcinogen in the infant mouse. Cancer Res 32(11):2289-2291
71. Shiota G, Harada K, Ishida M, Tomie Y, Okubo M, Katayama S, Ito H, Kawasaki H (1999) Inhibition of hepatocellular carcinoma by glycyrrhizin in diethylnitrosamine-treated mice. Carcinogenesis 20(1):59-63
72. Nikolaou K, Tsagaratou A, Eftychi C, Kollias G, Mosialos G, Talianidis I (2012) Inactivationof the deubiquitinase CYLD in hepatocytes causes apoptosis, infl ammation, fi brosis, and cancer. Cancer Cell 21(6):738-750. doi: 10.1016/j.ccr.2012.04.026
73. Weber A, Boger R, Vick B, Urbanik T, Haybaeck J, Zoller S, Teufel A, Krammer PH, Opferman JT, Galle PR, Schuchmann M, Heikenwalder M, Schulze-Bergkamen H (2010) Hepatocyte-specifi c deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology 51(4):1226-1236. doi: 10.1002/hep.23479
74. Hikita H, Kodama T, Shimizu S, Li W, Shigekawa M, Tanaka S, Hosui A, Miyagi T, Tatsumi T, Kanto T, Hiramatsu N, Morii E, Hayashi N, Takehara T (2012) Bak defi ciency inhibits liver carcinogenesis: a causal link between apoptosis and carcinogenesis. J Hepatol 57(1):92-100. doi: 10.1016/j.jhep.2012.01.027
75. Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S, Pinkert CA, Brinster RL, Palmiter RD (1989) Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 59(6):1145-1156
76. Kim CM, Koike K, Saito I, Miyamura T, Jay G (1991) HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351(6324):317-320. doi: 10.1038/351317a0
77. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K (1998) The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4(9):1065-1067. doi: 10.1038/2053
78. Ghoshal AK, Farber E (1984) The induction of liver cancer by dietary defi ciency of choline and methionine without added carcinogens. Carcinogenesis 5(10):1367-1370
79. Fan CY, Pan J, Usuda N, Yeldandi AV, Rao MS, Reddy JK (1998) Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J Biol Chem 273(25): 15639-15645
80. Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi C, Waguri S, Eishi Y, Hino O, Tanaka K, Mizushima N (2011) Autophagy-defi cient mice develop multiple liver tumors. Genes Dev 25(8):795-800. doi: 10.1101/gad.2016211
81. Inami Y, Waguri S, Sakamoto A, Kouno T, Nakada K, Hino O, Watanabe S, Ando J, Iwadate M, Yamamoto M, Lee MS, Tanaka K, Komatsu M (2011) Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J Cell Biol 193(2):275-284. doi: 10.1083/ jcb.201102031
82. Menon S, Yecies JL, Zhang HH, Howell JJ, Nicholatos J, Harputlugil E, Bronson RT, Kwiatkowski DJ, Manning BD (2012) Chronic activation of mTOR complex 1 is suffi cient to cause hepatocellular carcinoma in mice. Sci Signal 5(217):ra24. doi: 10.1126/ scisignal.2002739
83. Tang TC, Man S, Xu P, Francia G, Hashimoto K, Emmenegger U, Kerbel RS (2010) Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia 12(11):928-940
84. Feldman DE, Chen C, Punj V, Tsukamoto H, Machida K (2012) Pluripotency factormediated expression of the leptin receptor (OB-R) links obesity to oncogenesis through tumor-initiating stem cells. Proc Natl Acad Sci U S A 109(3):829-834. doi: 10.1073/pnas. 1114438109
85. Huynh H, Soo KC, Chow PK, Panasci L, Tran E (2006) Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res 12(14 Pt 1):4306-4314. doi: 10.1158/1078-0432.ccr-05-2568
86. Kashofer K, Tschernatsch MM, Mischinger HJ, Iberer F, Zatloukal K (2009) The disease relevance of human hepatocellular xenograft models: molecular characterization and review of the literature. Cancer Lett 286(1):121-128. doi: 10.1016/j.canlet.2008.11.011